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ABSTRACT Phencyclidine exerts psychotomimetic effects in humans and is used
as a pharmacological animal model for schizophrenia. We, and others, have demon-
strated that phencyclidine induces cognitive deficits in rats that are associated with
schizophrenia. These cognitive deficits can be normalized by inhibition of nitric oxide
synthase. The development of selective microelectrochemical nitric oxide sensors may
provide direct evidence for the involvement of nitric oxide in these effects. The aim of
the present study was to use LIVE (long term in vivo electrochemistry) to investigate
the effect of phencyclidine, alone or in combination with the nitric oxide synthase
inhibitor L-NAME, on nitric oxide levels in the medial prefrontal cortex of freely
moving rats. Phencyclidine (2 mg kg21) produced an increase in cortical nitric oxide
levels and this increase was ameliorated by L-NAME (10 mg kg21). Tentatively, the
results from the present study provide a biochemical rationale for the involvement of
nitric oxide in the phencyclidine model of schizophrenia. Synapse 63:1083–1088,
2009. VC 2009 Wiley-Liss, Inc.
INTRODUCTION
Nitric oxide (NO) is an unstable free radical gas,
and accumulated data suggest a pleiotropic role of
NO in physiological and pathophysiological mecha-
nisms both centrally and peripherally (Snyder and
Ferris, 2000). Interestingly, a number of studies have
suggested that NO might play an important role in
the action of the psychotomimetic NMDA-receptor
antagonist phencyclidine (PCP). Administration of
PCP to laboratory animals is commonly used to model
certain aspects of schizophrenia. The rationale for
this is that PCP can induce a state in humans that
closely resembles schizophrenia, encompassing both
positive and negative symptoms as well as cognitive
dysfunctions (Javitt, 2007; Luby et al., 1959). It has
been previously demonstrated that a wide range of
translational PCP-induced effects, including impair-
ments in preattentive information processing, nonas-
sociative learning, selective attention, spatial
learning, spatial reference memory, working
memory, and cognitive flexibility can all be prevented
by interfering with the production of NO (Johansson
et al., 1997; Klamer et al., 2001, 2004, 2005c; Wass
et al., 2006a,b). These findings suggest that the
schizophrenia-like behavioral effects of PCP in
rodents are, at least in part, mediated by an increase
in NO activity. This is supported by a recent study
showing a NO-dependent increase in cGMP signaling,
a main effector of NO in the brain, in the mouse pre-
frontal cortex following PCP-administration (Fejgin
et al., 2007). Furthermore, blocking the production of
cGMP in the prefrontal cortex prevented a PCP-
induced deficit in preattentive information processing
(Fejgin et al., 2007). In addition, a number of clinical
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studies suggest that aberrations in NO signaling may
be involved in the pathophysiology of schizophrenia
(for a review see Bernstein et al., 2005). Taken
together, these observations suggest that the NO path-
way may constitute an interesting target for novel
pharmacological therapies in schizophrenia and possi-
bly play a role in the pathophysiology of the disorder.
However, this contention rests on indirect evidence as
suitable tools for the real-time detection of NO in vivo
have, until recently, been lacking. In the present study,
the role of NO signaling in the behavioral and bio-
chemical effects of PCP was further investigated using
a novel NO-sensitive microelectrochemical sensor. The
sensor enables the recording of real-time NO levels in
awake, freely moving animals. In the first experiment
(denoted as Experiment 1, Department of Chemistry,
National University of Ireland, Maynooth) rats were
systemically treated with PCP to investigate a possible
effect on NO levels in the medial prefrontal cortex. The
prefrontal cortex was chosen based on its proposed role
in the cognitive dysfunction associated with schizo-
phrenia (Lewis and Moghaddam, 2006) and previously
published findings (Fejgin et al., 2007). In a second
experiment (denoted as Experiment 2, Department of
Pharmacology, University of Gothenburg, Sweden),
the dose-dependency of this effect was studied. Finally,
in a third experiment (denoted as Experiment 3,
Department of Pharmacology, University of Gothen-
burg, Sweden) the effect of pretreatment with the
nitric oxide synthase (NOS)-inhibitor, NG-nitro-L-argi-
nine methyl ester (L-NAME), on PCP-induced changes
in NO-levels in the prefrontal cortex was investigated.
METHODS
Animals
Male Wistar rats (UCD, Ireland, 280–400 g) were
used in Experiment 1 and male Sprague-Dawley rats
(Taconic, Denmark, 280–400 g) were used in Experi-
ments 2 and 3. All animals were housed, with a maxi-
mum of four per cage, in a colony room under con-
stant temperature (208C 6 18C) and humidity (50% 6
5%). Food and water were available ad libitum. The
daylight cycle was maintained artificially (lights on
from 0600 to 1800 h), and the experiments were con-
ducted during the light phase. The animals were
allowed to acclimatize for at least 1 week prior to sur-
gery. All experimental procedures used in the present
study were approved by the National University of
Ireland Maynooth Ethics Committee (Animal Experi-
mentation) and the Ethics Committee for Animal
Experiments, Goteborg, Sweden respectively.
Drugs
Phencyclidine hydrochloride (PCP, Sigma Chemi-
cals, St Louis, MO) and L-NAME (RBI, Natick, USA)
were used in the present study. PCP and L-NAME
were dissolved in saline (0.9% NaCl) and injected sub-
cutaneously (s.c.) in a volume of 2 ml kg21. The doses
of PCP and L-NAME used were based on previously
published studies (Johansson et al., 1997; Klamer
et al., 2005c; Wass et al., 2006a).
Surgical procedure
The rats were anesthetized with isoflurane, placed
in a Kopf stereotaxic instrument and kept on a heat-
ing pad to prevent hypothermia. An incision was
placed down the midline of the skull and the bone
was exposed. Four holes for the anchor screws, two
holes for the reference (8T Ag wire, 200-lm bare di-
ameter; Advent Research Materials, UK) and auxil-
iary (8T Ag wire) electrodes, and one or two holes for
the sensor electrodes were drilled. Electrodes were
then implanted following a previously described pro-
cedure (Lowry et al., 1997). The coordinates used for
the medial prefrontal cortex relative to bregma were
as follows: anterior 13.2 mm, lateral to midline 60.8
mm, and ventral -5.2 (Experiment 1) or -4.2 (Experi-
ments 2 and 3) mm from the brain surface. The elec-
trodes were inserted into the brain and connected to
a pedestal that was secured to the anchor screws
with dental cement. During surgery, the rats were
administered 2.0 ml of saline, to reduce postoperative
dehydration and an analgesic (buprenorphine or car-
profen) to reduce postoperative pain. The animals
were allowed to recover for 2–4 days before commenc-
ing experiments. They were housed individually in
standard plastic cages.
Electrochemical detection of NO
Prefrontal cortex NO levels were determined using a
NO selective amperometric microsensor. The microsen-
sor is a Nafion1-modified Pt disk electrode (patent no.
S2007/00,774). The sensor design has been validated
for in vitro and in vivo NO sensitivity (Brown et al.,
2005; Finnerty, 2008) and in vitro selectivity against
ascorbic acid, uric acid, and dopamine (Brown and
Lowry, 2003). The NO oxidation current (electrode
potential of 10.90 V against a Ag reference electrode)
was detected using a low-noise potentiostat (Experi-
ment 1: ACM Instruments, United Kingdom; Experi-
ment 2: Biostat II, Electrochemical and Medical Sys-
tems, UK) and converted using an A/D converter
(PowerLab, ADInstruments, United Kingdom). The
digital signal was then recorded using Chart software
(v5, ADInstruments) running on a PC. Individual
sensors were tested for ascorbic acid interference
and calibrated to ensure NO sensitivity in vitro prior
to surgery. Each animal was connected to the in vivo
voltammetry equipment on the day before an experi-
ment to allow the NO oxidation current to reach a
stable baseline. All experiments were carried out with
the animal in its home cage. For Experiment 1, two or
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four sensors were implanted bilaterally in the prefron-
tal cortex of five rats (total sensor n 5 12, right
hemisphere n 5 6, left hemisphere n 5 6). After
recovery the animal was subjected to PCP (2 mg kg21)
treatment. Saline was administered prior to PCP (2
mg kg21) to control for effects related to the injection
procedure. For Experiment 2, two sensors were
implanted in the prefrontal cortex of four rats. After
recovery each animal was subjected to four-drug treat-
ments with a 2-day washout period between each
treatment. The drug treatments were saline, PCP (1
mg kg21), PCP (2 mg kg21), and PCP (4 mg kg21) and
the order of the drug combinations was varied between
animals in a semirandomized manner. Finally for
Experiment 3, one sensor was implanted unilaterally
(the number of animals was balanced with respect to
right and left hemisphere) in the prefrontal cortex of
eight rats. After recovery each animal was subjected to
four-drug treatment combinations with a 2-day
washout period between each treatment. The drug
combinations were saline 1 saline, L-NAME (10 mg
kg21) 1 saline, saline 1 PCP (2 mg kg21), and
L-NAME (10 mg kg21) 1 PCP (2 mg kg21). The drug
combinations were administered with a 10-min inter-
val between the two injections and the order of the
drug combinations was varied between animals in a
semirandomized manner.
Probe placement verification
After termination of the experiments the rats were
decapitated. The brains were removed and fixated
(Accustain, Sigma-Aldrich) or frozen at 2808C. Sensor
placement was verified by sectioning the brains using
a vibratome or cryostat and an atlas of the rat brain
for reference. All sensors were verified to be posi-
tioned within the prelimbic or infralimbic part of the
prefrontal cortex at 3.2 6 0.4 mm anterior of bregma.
Data and statistical analysis
The NO oxidation current over time (sampling rate
4/s) recorded in chart was used as data. The mean of
the sampling period (5 min) immediately prior to
drug treatment was used as a baseline. For Experi-
ments 1 and 3, the mean current change from base-
line was calculated for a 5-min sampling period sur-
rounding the time points of 30, 60, and 90 min after
injection. This time frame was chosen to facilitate
comparison with previously published behavioral
studies (Johansson et al., 1997; Klamer et al., 2005b;
Wass et al., 2006a). For Experiment 2, the area under
the curve for a 180-min time period following drug
administration was calculated using GraphPad soft-
ware. To investigate whether the drug treatments
had any significant effect on NO levels, one or two
way analysis of variance (ANOVA) was performed as
specified in the Results section. The ANOVAs were
followed by Bonferroni’s test for comparisons between
groups where appropriate. Two tailed levels of signifi-
cance were used and P < 0.05 was considered statisti-
cally significant. Additionally, data from the left and
right hemisphere were compared in Experiment 1
using an unpaired t test to investigate a potential dif-
ference in NO response after PCP treatment. Since
the two experiments used different strains of rats an
unpaired t test was performed to control for an effect
of strain in the effects of PCP on NO levels.
RESULTS
Experiment 1
Systemic administration of PCP resulted in a pro-
longed increase in NO release in the prefrontal cortex
(Fig. 1A). Analysis of the NO oxidation current
change during the sampling period 60 min after PCP
administration did not reveal a significant difference
between the left and right hemisphere. Consequently,
the data were pooled for further analysis. A one-way
repeated measures ANOVA with treatment as within
subjects factor revealed a significant increase in NO
levels after PCP (2 mg kg21) administration (F(3,11)
5 15.633, P < 0.001, Fig. 1B). The Bonferroni test
showed that all the three time points (30, 60, 90 min)
following PCP administration were significantly dif-
ferent to the saline condition (P < 0.001, P < 0.01,
and P < 0.01, respectively).
Experiment 2
Similar to Experiment 1, PCP induced an increase
in NO levels. Analysis of the AUC for 180 min
(Fig. 2) following drug administration using a one-
way repeated measures ANOVA with dose (0, 1, 2,
and 4 mg kg21) as within subjects factor revealed a
significant dose-dependency of the PCP effect (F(3,18)
5 6.957, P < 0.01). The following Bonferroni test
showed that the PCP (2 mg kg21) AUC was signifi-
cantly different to saline (P < 0.05).
Experiment 3
As in Experiment 1, PCP induced an increase in
NO levels (Fig. 3A). The mean increase in NO levels
after PCP treatment (at 60 min) was lower in Experi-
ment 2 (22 6 10 pA) compared to Experiment 1 (48 6
37 pA), although the difference did not quite reach
statistical significance (unpaired t test, t 5 -1.903, df
5 18, P 5 0.073). The observed increase in NO oxida-
tion current was ameliorated by pretreatment with
L-NAME, which in itself reduced NO levels. A two-
way repeated measures ANOVA with time and treat-
ment as within subjects factors revealed a main effect
of time (F(2,7) 5 4.499, P < 0.05), treatment (F(3,7)
5 12.064, P < 0.001) and an interaction between time
and treatment (F(6,7) 5 2.682, P < 0.05). Given this
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interaction, each time point (30, 60, 90 min) was ana-
lyzed separately using a two-way repeated measures
ANOVA with pretreatment (saline or L-NAME) and
treatment (saline or PCP) as within-subject factors.
For the 30-min sampling period (Fig. 3B) the ANOVA
revealed a main effect of pretreatment (F(1,7) 5
14.992, P < 0.01), treatment (F(1,7) 5 8.944, P <
0.05) and a significant interaction between pretreat-
ment and treatment (F(1,7) 5 16.565, P < 0.01). The
analysis of the 60-min sampling period (Fig. 3B) on
the other hand showed a main effect of pretreatment
(F(1,7) 5 15.830, P < 0.01) and treatment (F(1,7) 5
9.838, P < 0.05) but no significant interaction
between the factors. Similarly, the ANOVA for the 90-
min sampling period (Fig. 3B) showed a main effect
of pretreatment (F(1,7) 5 8.150, P < 0.05) and treat-
ment (F(1,7) 5 7.220, P < 0.05) but again no signifi-
cant interaction between the factors was found.
DISCUSSION
An important finding of the present study was that
the psychotomimetic drug, PCP, was found to induce
Fig. 2. The NO oxidation current AUC for a 180-min time pe-
riod medial after saline and PCP (1, 2, and 4 mg kg21) administra-
tion in four rats (sensor n 5 7). All animals received each treatment
in a semirandomized order with a 2-day washout period between
each drug administration. Data is expressed as mean 6 SEM AUC
(pAs) as compared to baseline. a P < 0.05 vs. saline.
Fig. 3. (A) A representative voltammogram showing the NO oxi-
dation current in the medial prefrontal cortex after SAL1SAL,
SAL1PCP (2 mg kg21) and L-NAME (10 mg kg21) 1PCP (2 mg
kg21) administration as indicated in the figure. Data is expressed as
current (pA) over time (seconds). (B) The mean change at 30, 60,
and 90 min in prefrontal cortex NO levels as compared to baseline
in eight rats (sensor n 5 8). All animals received each treatment in
a semirandomized order with a 2-day washout period between each
drug combination (saline 1saline, L-NAME 1 saline, saline 1 PCP
and L-NAME 1 PCP). Data is expressed as mean 6 SEM current
change (pA) over a 5-min sampling period at 30, 60, and 90 min af-
ter the second drug administration.
Fig. 1. (A) A representative voltammogram showing the NO oxi-
dation current in the medial prefrontal cortex after PCP (2 mg
kg21, t 5 0) administration. Data is expressed as current (pA) over
time (seconds). (B) The mean change at 30, 60, and 90 min in
medial prefrontal cortex NO levels after PCP (2 mg kg21, t 5 0)
administration as compared to saline administration in five rats
(sensor n 5 12). Data is expressed as mean 6 SEM current change
(pA) after saline administration or the mean of a 5-min sampling
period at 30, 60, and 90 min after PCP administration. a, P < 0.001
and b, P < 0.01 vs. saline.
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a dose-dependent increase in brain NO levels, thus
corroborating previous indirect evidence of this effect
of PCP. In addition, the PCP-induced elevation of NO
could be counteracted by pretreatment with the NOS
inhibitor, L-NAME, in a dose that has previously
been shown to block the behavioral effects of PCP in
translational animal models of schizophrenia
(Johansson et al., 1997; Klamer et al., 2005c; Wass
et al., 2006a,b).
There was a trend (P 5 0.10) towards a higher
increase in NO after PCP treatment in Experiment 1
compared to Experiment 2. This may be an effect of
strain or due to the difference in sensor placement
and future experiments may clarify this. However,
PCP induced an increase in NO levels in both Wistar
and Sprague-Dawley rats, which shows that this
effect of PCP is not restricted to a specific strain of
rats only. In vitro calibration data indicate that the
observed mean increase in NO levels was 24 nM in
Experiment 1 and 13 nM in Experiment 2. This
increase is substantial compared to estimated NO lev-
els of 0.1 nM (reviewed in Hopper and Garthwaite,
2006). This value is derived from a different methodo-
logical approach, but it may be that extracellular NO
levels in the brain may be higher than previously
estimated. However, it should also be noted that the
calculated NO levels in the present study are derived
from in vitro precalibration data and it remains to be
shown that this fully equates the in vivo changes in
NO oxidation current. Additionally, the relationship
between the changes in NO observed in the present
study and synaptic NO levels is unclear. Synaptic lev-
els of NO are thought to be in the very low nanomolar
range (reviewed in Garthwaite, 2008). Given the
amplitude and sustained effect on NO levels, the
present observations may be more related to neuro-
vascular or volume transmission effects of NO rather
than events occurring at discrete synapses. Impor-
tantly, several genetic and biochemical studies
support the involvement of NO, and downstream NO-
signaling in the form of cGMP, in the behavioral
effects of PCP. Mice lacking the NOS-1 (Bird et al.,
2001; Klamer et al., 2005a) or PDE-1 (Siuciak et al.,
2007) genes display an altered sensitivity to the be-
havioral effects of PCP. In addition, PCP shows an
increased cGMP production both in vitro (Vesely,
1979) and in vivo (Fejgin et al., 2007). Interestingly, a
recent study demonstrated a prolonged NO increase
of 8 nM in the medial prefrontal cortex following co-
caine administration in anesthetized rats (Sammut
and West, 2008). This implies that an increase in NO
levels may be a common denominator of psychostimu-
lants; a notion that warrants further experiments.
The effect over time curves in the present study
(see Figs. 1 and 3) indicated that the peak effect of
PCP on NO levels at least partially overlaps with the
effect on preattentive information processing as
shown in previous studies (Klamer et al., 2005b), sug-
gesting a temporal correlation of increased NO levels
and deficits in preattentive information processing
following systemic PCP administration in rats. How-
ever, the mechanism by which PCP increases brain
NO levels remains to be determined. Increased activ-
ity of NOS-1 (see below) in the brain has been
coupled to NMDA-receptor activation and subsequent
Ca21 influx. Logically, this source of Ca21 cannot
explain the present effects as PCP is a potent NMDA-
receptor antagonist (Javitt, 2007). However, it has
been shown that PCP can induce an increased release
of glutamate in the frontal cortex of rats (Adams and
Moghaddam, 2001). This could lead to an activation
of AMPA receptors permeable to Ca21 and a subse-
quent AMPA receptor-mediated NO production
(Fedele and Raiteri, 1999; Zhou et al., 2006).
L-NAME in a dose of 10 mg kg21 has been shown
to block a number of PCP-induced behavioral effects
in rats, including a deficit in prepulse inhibition,
hyperactivity, abnormal latent inhibition and deficits
in spatial learning and working memory (Johansson
et al., 1997; Klamer et al., 2005c; Wass et al.,
2006a,b). The present study provides a biochemical
rationale for these effects as PCP induced an increase
in NO levels and that effect was attenuated by pre-
treatment with L-NAME in a dose of 10 mg kg21.
This dose of L-NAME also lowered NO levels by itself.
The absence of a significant pretreatment 3 treat-
ment interaction at the 60- and 90-min sampling peri-
ods suggest that the effect of L-NAME on the PCP-
induced increase in NO levels may be best explained
as a combination of a true interaction and an additive
effect. Thus, it may be that L-NAME and PCP exert
their opposing effects on NO levels partly via differ-
ent signaling pathways. However, the analysis of the
30-min sampling period showed a significant pretreat-
ment 3 treatment interaction which implies a func-
tional connection via the NO system. In addition,
L-NAME has been shown to block a PCP-induced
increase in cGMP levels in the prefrontal cortex of
mice, without affecting baseline cGMP levels (Fejgin
et al., 2007).
In summary, the present study demonstrates a
long-lasting PCP-induced release of NO in the brain
of awake, freely moving animals. Thus, this study
provides the first direct biochemical evidence for an
involvement of NO in the effects of PCP. This has pre-
viously been suggested though behavioral pharmacol-
ogy data and indirect measures of NO activity (Fejgin
et al., 2007; Klamer et al., 2005b). In addition, the
present results indicate that a PCP-induced increase
in NO levels can be attenuated by the NOS-inhibitor
L-NAME, in a dose that has been shown to be effec-
tive in ameliorating schizophrenia-related behavioral
effects of PCP. This suggests that the ability of
L-NAME to block PCP-induced behavior is directly
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related to an additive effect on NO levels by the two
compounds. This highlights the potential of the NO
pathway as a future target for novel treatment
rationales in schizophrenia.
ACKNOWLEDGMENTS
The authors gratefully acknowledge the technical
assisstance of Joseph Fernando and helpful discus-
sions with Dr. Jeffrey C. Glennon.
REFERENCES
Adams BW, Moghaddam B. 2001. Effect of clozapine, haloperidol, or
M100907 on phencyclidine-activated glutamate efflux in the pre-
frontal cortex. Biol Psychiatry 50:750–757.
Bernstein HG, Bogerts B, Keilhoff G. 2005. The many faces of nitric
oxide in schizophrenia. A review. Schizophr Res 78:69–86.
Bird DC, Bujas-Bobanovic M, Robertson HA, Dursun SM. 2001.
Lack of phencyclidine-induced effects in mice with reduced
neuronal nitric oxide synthase. Psychopharmacology (Berl) 155:
299–309.
Brown FO, Lowry JP. 2003. Microelectrochemical sensors for in vivo
brain analysis: An investigation of procedures for modifying Pt
electrodes using Nafion. Analyst 128:700–705.
Brown FO, Finnerty NJ, Bolger FB, Millar J, Lowry JP. 2005. Cali-
bration of NO sensors for in-vivo voltammetry: Laboratory synthe-
sis of NO and the use of UV-visible spectroscopy for determining
stock concentrations. Anal Bioanal Chem 381:964–971.
Fedele E, Raiteri M. 1999. In vivo studies of the cerebral glutamate
receptor/NO/cGMP pathway. Prog Neurobiol 58:89–120.
Fejgin K, Palsson E, Wass C, Svensson L, Klamer D. 2007. Nitric
oxide signaling in the medial prefrontal cortex is involved in the
biochemical and behavioral effects of phencyclidine. Neuropsycho-
pharmacology 33:1874–1883.
Finnerty NJ. 2008. Electrochemical Sensors: In-vitro and in-vivo
analysis of brain nitric oxide and regional cerebral blood flow.
PhD Thesis. Maynooth: National University of Ireland Maynooth.
Garthwaite J. 2008. Concepts of neural nitric oxide-mediated trans-
mission. Eur J Neurosci 27:2783–2802.
Hopper RA, Garthwaite J. 2006. Tonic and phasic nitric oxide sig-
nals in hippocampal long-term potentiation. J Neurosci 26:11513–
11521.
Javitt DC. 2007. Glutamate and Schizophrenia: Phencyclidine. N-
methyl-D-aspartate receptors, and dopamine–glutamate interac-
tions. Int Rev Neurobiol 78:69–108.
Johansson C, Jackson DM, Svensson L. 1997. Nitric oxide synthase
inhibition blocks phencyclidine-induced behavioural effects on pre-
pulse inhibition and locomotor activity in the rat. Psychopharma-
cology (Berl) 131:167–173.
Klamer D, Engel JA, Svensson L. 2001. The nitric oxide synthase
inhibitor. L-NAME, block phencyclidine-induced disruption of pre-
pulse inhibition in mice. Psychopharmacology (Berl) 156:182–186.
Klamer D, Palsson E, Revesz A, Engel JA, Svensson L. 2004. Habit-
uation of acoustic startle is disrupted by psychotomimetic drugs:
Differential dependence on dopaminergic and nitric oxide modula-
tory mechanisms. Psychopharmacology (Berl) 176:440–450.
Klamer D, Engel JA, Svensson L. 2005a. Effects of phencyclidine on
acoustic startle and prepulse inhibition in neuronal nitric oxide
synthase deficient mice. Eur Neuropsychopharmacol 15:587–590.
Klamer D, Palsson E, Fejgin K, Zhang J, Engel JA, Svensson L.
2005b. Activation of a nitric-oxide-sensitive cAMP pathway with
phencyclidine: elevated hippocampal cAMP levels are temporally
associated with deficits in prepulse inhibition. Psychopharmacol-
ogy (Berl) 179:479–488.
Klamer D, Palsson E, Wass C, Archer T, Engel JA, Svensson L.
2005c. Antagonism of the nitric oxide synthase inhibitor.
L-NAME, of the effects of phencyclidine on latent inhibition in
taste aversion conditioning. Behav Brain Res 161:60–68.
Lewis DA, Moghaddam B. 2006. Cognitive dysfunction in schizo-
phrenia: Convergence of gamma-aminobutyric acid and glutamate
alterations. Arch Neurol 63:1372–1376.
Lowry JP, Boutelle MG, Fillenz M. 1997. Measurement of brain
tissue oxygen at a carbon paste electrode can serve as an index of
increases in regional cerebral blood flow. J Neurosci Methods
71:177–182.
Luby ED, Cohen BD, Rosenbaum G, Gottlieb LS, Kelly R. 1959.
Study of a new schizophrenomimetic drug-sernyl. Arch Neurol
Psychiatry 81:363–369.
Sammut S, West AR. 2008. Acute cocaine administration increases
NO efflux in the rat prefrontal cortex via a neuronal NOS-depend-
ent mechanism. Synapse 62:710–713.
Siuciak JA, McCarthy SA, Chapin DS, Reed TM, Vorhees CV,
Repaske DR. 2007. Behavioral and neurochemical characteriza-
tion of mice deficient in the phosphodiesterase-1B (PDE1B)
enzyme. Neuropharmacology 53:113–124.
Snyder SH, Ferris CD. 2000. Novel neurotransmitters and their
neuropsychiatric relevance. Am J Psychiatry 157:1738–1751.
Vesely DL. 1979. Phencyclidine stimulates guanylate cyclase activ-
ity. Biochem Biophys Res Commun 88:1244–1248.
Wass C, Archer T, Palsson E, Fejgin K, Alexandersson A, Klamer D,
Engel JA, Svensson L. 2006a. Phencyclidine affects memory in a
nitric oxide-dependent manner: Working and reference memory.
Behav Brain Res 174:49–55.
Wass C, Archer T, Palsson E, Fejgin K, Klamer D, Engel JA, Svens-
son L. 2006b. Effects of phencyclidine on spatial learning and
memory: Nitric oxide-dependent mechanisms. Behav Brain Res
171:147–153.
Zhou Y, Zhou L, Chen H, Koliatsos VE. 2006. An AMPA glutamater-
gic receptor activation-nitric oxide synthesis step signals transsy-
naptic apoptosis in limbic cortex. Neuropharmacology 51:67–76.
1088 E. PA˚LSSON ET AL.
Synapse
